PIDD inhibitors, also known as phosphoinositide 3-kinase delta (PI3Kδ) inhibitors, belong to a distinct chemical class of compounds that play a pivotal role in modulating cellular signaling pathways. PI3Ks are a family of lipid kinases responsible for catalyzing the phosphorylation of phosphatidylinositol lipids at the 3-position of the inositol ring, leading to the production of secondary messengers involved in various cellular processes. The PI3K family is categorized into different isoforms, and PI3Kδ is primarily expressed in immune cells, particularly in lymphocytes, where it participates in regulating immune responses. PIDD inhibitors specifically target the PI3Kδ isoform and act by disrupting the activity of this kinase. At the molecular level, PIDD inhibitors exert their effects by binding to the ATP-binding pocket within the catalytic domain of the PI3Kδ enzyme. This binding inhibits ATP, the cellular energy currency, from accessing the active site and being utilized for phosphorylation reactions. As a consequence, the downstream signaling pathways that depend on the phosphorylation of phosphatidylinositol lipids are disrupted.
By inhibiting PI3Kδ, PIDD inhibitors influence critical intracellular pathways, including the well-characterized PI3K/AKT/mTOR pathway. This pathway plays a central role in cell growth, proliferation, survival, and metabolism. Moreover, PI3Kδ is intricately involved in regulating immune responses, such as B-cell receptor signaling and the activation of T cells. Therefore, PIDD inhibitors are recognized for their ability to modulate immune cell function. In summary, PIDD inhibitors comprise a distinct class of compounds designed to selectively inhibit the PI3Kδ isoform. By binding to the ATP-binding pocket of PI3Kδ, these inhibitors disrupt cellular signaling cascades, with implications spanning diverse cellular functions, including cell growth, survival, and immune response regulation. This detailed understanding of the molecular mechanism behind PIDD inhibitors paves the way for exploring their broader implications in both basic research and applications.
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Wortmannin | 19545-26-7 | sc-3505 sc-3505A sc-3505B | 1 mg 5 mg 20 mg | $67.00 $223.00 $425.00 | 97 | |
Irreversible inhibitor of PI3K by binding to its active site, preventing the phosphorylation of phosphatidylinositol lipids. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $123.00 $400.00 | 148 | |
Reversible inhibitor of PI3K, competes with ATP for binding to the kinase domain, blocking downstream signaling. | ||||||
ZSTK 474 | 475110-96-4 | sc-475495 | 5 mg | $75.00 | ||
Potent inhibitor of multiple PI3K isoforms, disrupting PI3K/AKT/mTOR pathway signaling. | ||||||
BKM120 | 944396-07-0 | sc-364437 sc-364437A sc-364437B sc-364437C | 5 mg 10 mg 25 mg 50 mg | $176.00 $235.00 $281.00 $339.00 | 9 | |
Oral pan-PI3K inhibitor that blocks PI3K signaling by targeting the ATP-binding pocket of the PI3K catalytic subunit. | ||||||
CAL-101 | 870281-82-6 | sc-364453 | 10 mg | $193.00 | 4 | |
Selective inhibitor of PI3Kδ, mainly used for certain blood cancers by blocking B-cell receptor signaling. | ||||||
BAY 80-6946 | 1032568-63-0 | sc-503264 | 5 mg | $562.00 | ||
Potent PI3K inhibitor that targets both PI3Kα and PI3Kδ isoforms, used for relapsed follicular lymphoma. | ||||||
BYL719 | 1217486-61-7 | sc-391001 sc-391001A sc-391001B sc-391001C sc-391001D sc-391001E | 5 mg 10 mg 50 mg 100 mg 500 mg 1 g | $391.00 $597.00 $755.00 $1192.00 $5000.00 $9370.00 | 2 | |
PI3Kα-specific inhibitor used in combination therapy for hormone receptor-positive, HER2-negative breast cancer. | ||||||
GDC-0941 | 957054-30-7 | sc-364498 sc-364498A | 5 mg 10 mg | $188.00 $199.00 | 2 | |
A PI3K inhibitor, targeting multiple isoforms, suppressing the PI3K/AKT/mTOR pathway. | ||||||